By  Henry Owino (Senior Correspondent)

The eResearch Technology (ERT) has been recognized for innovation in accelerating the clinical development of new medical treatments.

The ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence.

The company has been named the Health IT Innovator of the Year, by the Pittsburgh Technology Council. The award was presented on September 25 during the annual Tech 50 Gala.

With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what is next, so it can adapt without compromising standards.

ERT has been recognized for its suite of innovative clinical trial solutions that pharmaceutical researchers rely on to determine the safety and effectiveness of new medical treatments.

By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly and with confidence.

The Tech 50 Awards program recognizes the companies that are impacting their customers and driving the success of the Pittsburgh region and the industry at large through innovative ideas and state-of-the-art technologies.

Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date.

ERT’s electronic Clinical Outcome Assessment (eCOA), Cardiac Safety, Respiratory, Imaging, Real World Evidence and Trial Oversight solutions improve clinical trial efficiencies, overcome the limitations of traditional paper-driven approaches, and deliver the highest quality patient data.

So its biopharmaceutical customers can accelerate clinical development, getting novel treatments to patients sooner. ERT’s eClinical solutions have been used in the development of more than half of all drugs approved by the FDA since 2013.

“We are very honored and grateful to the Tech 50 judging panel for identifying ERT among a crowded field of innovative companies in the Pittsburgh region,” said James M. Corrigan, President and CEO, ERT.

“This award really represents the hard work our employees do every day in Pittsburgh, and around the globe and their commitment to delivering the solutions and services our customers rely on as they develop new medical treatments for patients worldwide.” President/CEO, Corrigan affirmed.

ERT, formerly known as Cardio Data Systems, was founded in 1972 and analyzed ambulatory Holter electrocardiograms and conducted its first research study in 1975.

By the end of that year the company expanded into the largest US Holter monitoring research provider of evaluating cardiovascular drugs for approval by the US Food and Drug Administration (FDA).

In 1979, the company analyzed 4,500 Holter readings for the National Institutes of Health’s Beta Blocker Heart Attack Trial. The study resulted in the recommendation to use the drug propranolol for at least three years in patients who have had a recent heart attack and who need to have their heart rate slowed down.

For more information on ERT’s suite of eClinical solutions, visit

This site uses Akismet to reduce spam. Learn how your comment data is processed.